Objective: Adults with early-onset type 2 diabetes (T2D, diagnosed

<age 40)="" experience="" premature="" and="" more="" severe="" cardiovascular="" complications.="" we="" investigated="" cumulative="" hyperglycemia="" insulin="" resistance="" (ir)="" over="" 25="" years="" in="" patients="" with="" early-onset="" t2d="" related="" to="" cardiac="" dysfunction="" midlife.="" Methods: We used Coronary Artery Risk Development in Young Adults study (CARDIA, Year 0 to 25) data. Early-onset T2D was self-reported or by fasting glucose (FG)≥126 or oral glucose≥200 mg/dL at/before Year 10. Left ventricular systolic function was estimated by ejection fraction and global longitudinal strain (GLS); diastolic function by early peak diastolic mitral annular velocity, e’, and mitral E/e′. We used the area under the growth curve (AUC) derived from quadratic random-effects models of≥4 repeated measures of FG and HOMA-IR to estimate the cumulative burden of T2D. We performed linear regressions to examine the associations of the total AUC of FG or HOMA-IR with echocardiographic outcomes, accounting for sex, race, education, mid-life age, smoking, alcohol drinking, hypertension, hyperlipidemia, diabetic medication, and heart rate.

Results: We included 271 CVD-free patients with early-onset T2D and 514 sociodemographic-matched individuals with euglycemia. In adjusted models, an SD higher AUC of FG was significantly associated with the worsening of diastolic function (β coefficients for e’= - 0.18 and E/e’=0.27) and marginally associated with the worsening of GLS (β=0.13). However, these associations were not significant in the euglycemia group. One SD higher AUC of HOMA-IR was associated with the worsening of e’ and GLS irrespective of T2D status (e’ β= -0.2 and -0.16, and GLS β=0.13 and 0.19 in T2D and euglycemia, respectively).

Conclusion: Cumulative hyperglycemia alters midlife diastolic function in patients with early-onset T2D. Sustained IR negatively affects both systolic and diastolic function regardless of T2D status.

Disclosure

Y. Yoshida: None. K.C. Ferdinand: Consultant; Amgen Inc., Novartis Pharmaceuticals Corporation, Lilly Diabetes, Janssen Pharmaceuticals, Inc., Medtronic, Boehringer-Ingelheim. D. Aguilar: None. V. Fonseca: Consultant; Abbott, Bayer Inc. Stock/Shareholder; BRAVO4HEALTH, LLC. Consultant; Corcept Therapeutics. Speaker's Bureau; Eli Lilly and Company. Research Support; Fractyl Health, Inc. Consultant; Sun Pharmaceutical Industries Ltd. Stock/Shareholder; Amgen Inc.

Funding

American Diabetes Association (7-23-JDFWH-10)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.